OKYO Pharma Limited Presentation of Preclinical Data (0782S)
07 March 2019 - 6:00PM
UK Regulatory
TIDMOKYO
RNS Number : 0782S
OKYO Pharma Limited
07 March 2019
OKYO Pharma Limited
("OKYO" or the "Company")
Presentation of Preclinical Data Demonstrating Potential of
OKYO-0101 for Dry Eye Treatment
'OKYO-0101 is a proprietary first-in-class GPCR agonist for
topical treatment of dry eye disease'
OKYO Pharma Limited (LSE: OKYO), a biotechnology company
developing targeted drugs for inflammatory eye diseases and chronic
pain, announces that it will present preclinical results
demonstrating anti-inflammatory activity and the potential of
OKYO-0101 for dry eye treatment. The presentation will take place
at the 'late-breaking poster session' of 14(th) Congress on Ocular
Pharmacology and Therapeutics, a biennial meeting of Association
for Ocular Pharmacology & Therapeutics (AOPT) in New Orleans
from 7-10 March 2019. The major theme of this year's meeting is
"Next Generation of Ocular Therapeutics".
The details of the presentation are:
Poster entitled "OKYO-0101, an agonist of G-protein coupled
receptor (GPCR), ameliorates inflammation in an experimental model
of dry eye disease in mice" will be presented at the 'late Breaking
Poster Session' from 17:30-19:00 on March 8(th) , 2019.
HIGHLIGHTS OF THE DATA
-- Increase in corneal permeability due to dry eye was reduced
significantly by topical treatment with OKYO-0101 as compared to
vehicle group.
-- Potency of OKYO-0101 in reducing corneal permeability was
comparable to cyclosporine, an active ingredient of Restasis(R)
(Allergan).
-- OKYO--0101 normalized the dry eye induced loss of goblet cell density.
-- OKYO-0101 reduced the dry eye induced-enhancement of CD4(+)
T-cells, which are known biomarkers of inflammation.
-- Rabbit ocular tolerance test using OKYO-0101 showed no
adverse signs such as inflammation, chemosis or hyperemia and signs
of local irritation.
-- Clinical ophthalmic exam of rabbit eyes after topical
application of OKYO-0101 for 4 days (twice daily) showed no
vascularization, discharge, edema, cloudiness or retinal
hemorrhage.
-- These preclinical data demonstrate potential of OKYO-0101 for treatment of dry eye disease.
"This exciting data represent a first important milestone
confirming 'Proof-of-Concept' in preclinical studies for
therapeutic potential of OKYO-0101 for dry eye disease" said Dr.
Raj Patil, Senior Director R&D, OKYO Pharma Limited.
About Dry Eye
Dry eye is a multifactorial disease caused by underlying
inflammation resulting in the lack of lubrication and moisture on
the surface of the eye. Symptoms of dry eye include constant
discomfort and irritation accompanied by inflammation of ocular
surface, visual impairment and potential damage to ocular surface.
Dry Eye affects over 35% of 50+ older population, with women
representing approximately two-thirds of those affected. Prevalence
of dry eye is expected to increase substantially in the near future
due to an aging population. Dry eye syndrome represents a major
economic burden in public healthcare accounting to total annual
cost for the management of disease to US economy more than $50
billion annually.
About OKYO-0101
OKYO-0101 is an agonist of Chemerin, which belongs to GPCR
family of receptors, that inhibits underlying inflammation causing
dry eye, uveitis and allergic conjunctivitis. Anti-inflammatory
action of OKYO-0101 follows a novel mechanism, which inhibits the
generation of proinflammatory mediators. OKYO-0101 is a proprietary
first-in-class topically administered GPCR agonist for dry eye.
About AOPT
AOPT is a global not-for-profit organization for scientists and
individuals from all disciplines related to ocular pharmacology and
its therapeutic applications. AOPT has a diverse, multi-national
membership composed of preclinical and clinical scientists,
students, and healthcare professionals. Members are from academic
institutions, pharma and biotech industries, device companies,
clinics and private practice. (Source: AOPT Website).
About OKYO
OKYO is a UK biotechnology company that focuses on the discovery
and development of novel molecules to treat inflammatory eye
diseases and chronic pain. In addition to OKYO-0101, the Company is
also developing OKYO-0201 for ocular and chronic pain.
End
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7382 8300
Andy Crossley
Antonio Bossi
Stockdale Securities Limited (Broker) David Coaten +44 (0)20 7601 6100
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUNSVRKOAORAR
(END) Dow Jones Newswires
March 07, 2019 02:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024